The PAMM Foundation outsources its pathology and medical microbiology (“PAMM”) laboratory activities to Eurofins Clinical Diagnostics Netherlands
LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, announces that it has successfully signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie (“PAMM”), a medical microbiology laboratory diagnostics company and pathology in the Netherlands.
PAMM serves 6 hospitals in the Netherlands, including 2 top clinical oncology centers, general practitioners and independent treatment centers. The lab specializes in medical microbiology and pathology and was the first in the Netherlands to implement fully digital pathology. PAMM employs more than 265 staff and pathologists and will complement Eurofins’ industry-leading global clinical testing offering. By combining its strengths, PAMM will be able to further improve customer quality and patient service in the Dutch healthcare system.
The agreement includes a commitment from Eurofins to invest in laboratory, R&D, innovation, employee development and job security. The agreement has been approved by the Dutch Healthcare Authority (NZa) and the Dutch Authority for Consumers and Markets (ACM, Merger Control).
Comment by Dr Gilles MartinCEO of Eurofins: “We are very pleased to welcome PAMM and its team of exceptional laboratory specialists and technicians to the Eurofins Group. This agreement reinforces the Group’s wide offer of innovative tests to hospitals and practitioners in the Netherlands, strengthens Eurofins’ geographical offer in the clinical tests market and improves our ability to deploy the latest scientific advances for the benefit of patients.
About Eurofins – the world leader in bio-analysis
Eurofins tests for life. Eurofins is the world leader in food, environmental, pharmaceutical and cosmetics testing, as well as contract research services in discovery pharmacology, forensic science, advanced materials science and agroscience. Eurofins is also a market leader in certain genomics testing and laboratory services, and clinical study support, as well as BioPharma contract development and manufacturing. The Group also has a rapidly developing presence in highly specialized and molecular clinical diagnostic tests and in vitro diagnostic products.
With 58,000 employees spread over a network of 900 laboratories in 54 countries, Eurofins companies offer a portfolio of more than 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.